The overall goal of this educational session is to discuss the potential benefits and risks of factor XI inhibitors in the fight against venous and arterial thromboembolism and bleeding risk reduction in the setting of Atrial Fibrillation (AFib), acute coronary syndrome (ACS), secondary stroke prevention and venous thromboembolism (VTE).
Accreditation Statement
In accordance with ACCME policy, prior to participating in this activity, you must review the information on this page.
Joint Accreditation Statement:
In support of improving patient care, the American College of Cardiology Foundation (ACCF) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.
Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Nurses:
The ACCF designates this educational activity for a maximum of 1.25 continuing nursing education contact hours.
Credit Designation Statement:
Physicians:
The ACCF designates this internet enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Associates:
AAPA Credit Designation Statement – Enduring Materials
The American College of Cardiology Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1,25 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until 04/18/2026 PAs should only claim credit commensurate with the extent of their participation.
Pharmacists:
ACCF designates this continuing education activity for 1.25 contact hours of the Accreditation Council for Pharmacy Education. ACPE Universal Activity Number (UAN): JA4008225-0000-25-009-H01-P (Pharmacists); JA4008225-0000-25-009-H01-T (Pharmacist Technicians).
Interprofessional Continuing Education (ICPE) Credit:
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
Target Audience:
This course is intended for physicians, nurses, pharmacists, physician associates and the cardiovascular care team.
Important Dates:
Date of Release: April 18, 2025
Term of Approval/Date of Expiration: April 18, 2026
Learner Objectives:
Upon completion of this program, attendees should be able to:
- Compare and contrast vitamin K agonists (VKA), direct oral anticoagulant (DOAC), and factor XI inhibitors
- Discuss the role of FXI in hemostasis and thrombosis
- Summarize completed clinical trials on FXI inhibitors
- Employ multidisciplinary approaches for developing effective care pathways
Grant Acknowledgement:
Educational grant support for this activity provided by the Bristol Myers Squibb and Janssen Pharmaceuticals, Inc. Alliance.
Faculty:
Geoffrey Barnes, MD, MSc, FACC
Marc Bonaca, MD, FACC
Jean M. Connors, MD
Robert Harrington, MD, MACC
Kristen Bova Campbell, PHARMD, FACC